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Abstract
Background: Urinary calprotectin has been identified as a promising biomarker for acute
kidney injury. To date, however, the time-dependent changes of this parameter during
acute kidney injury remain elusive. The aim of the present work was to define the time-
course of urinary calprotectin secretion after ischaemia/reperfusion-induced kidney injury in
comparison to neutrophil gelatinase—associated lipocalin, thereby monitoring the extent of
tubular damage in nephron sparing surgery for kidney tumours. Methods: The study popula-
tion consisted of 42 patients. Thirty-two patients underwent either open or endoscopic neph-
ron sparing surgery for kidney tumours. During the surgery, the renal arterial pedicle was
clamped with a median ischaemic time of 13 minutes (interquartile range, 4.5–20.3 minutes)
in 26 patients. Ten retro-peritoneoscopic living donor nephrectomy patients and 6 nephron
sparing surgery patients in whom the renal artery was not clamped served as controls. Uri-
nary calprotectin and neutrophil gelatinase—associated lipocalin concentrations were
repeatedly measured by enzyme-linked immunosorbent assay and assessed according to
renal function parameters. Results: Urinary concentrations of calprotectin and neutrophil
gelatinase—associated lipocalin increased significantly after ischaemia/reperfusion injury,
whereas concentrations remained unchanged after nephron sparing surgery without
ischaemia/reperfusion injury and after kidney donation. Calprotectin and neutrophil gelati-
nase—associated lipocalin levels were significantly increased 2 and 8 hours, respectively,
post-ischaemia. Both proteins reached maximal concentrations after 48 hours, followed by
a subsequent persistent decrease. Maximal neutrophil gelatinase—associated lipocalin
and calprotectin concentrations were 9-fold and 69-fold higher than their respective base-
line values. The glomerular filtration rate was only transiently impaired at the first post-oper-
ative day after ischaemia/reperfusion injury (p = 0.049). Conclusion: Calprotectin and
neutrophil gelatinase—associated lipocalin can be used to monitor clinical and sub-clinical
tubular damage after nephron sparing surgery for kidney tumours. Urinary calprotectin con-
centrations start rising within 2 hours after ischaemia/reperfusion-induced kidney injury.
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Introduction
Calprotectin in the urine has recently been identified as a promising biomarker for acute kid-
ney injury (AKI) [1,2]. It can differentiate between intrinsic and prerenal causes of AKI. Cal-
protectin is a calcium-binding complex comprising 2 proteins of the so-called S100 group
(S100A8/S100A9). Calprotectin is a mediator protein of the innate immune system calprotec-
tin, and it is released by monocytes and neutrophils as a danger-associated molecular pattern
protein [3]. Additionally, renal collecting duct epithelial cells produce S100A8 and S100A9 in
response to renal injury [4]. Whereas calprotectin levels in prerenal disease are comparable to
healthy controls, intrinsic AKI leads to highly increased calprotectin concentrations. In a study
population of 188 subjects, calprotectin achieved a high diagnostic performance in the differen-
tiation of intrinsic and prerenal AKI. Urinary calprotectin concentrations were 50-fold higher
in intrinsic AKI than in prerenal AKI. In that study population, calprotectin achieved a higher
diagnostic performance than neutrophil gelatinase—associated lipocalin (NGAL) in the differ-
entiation between prerenal and intrinsic AKI [1]. Calprotectin is not only an AKI marker; it
can also mediate AKI. In a S100A9-knockout mouse model, it was recently demonstrated that
calprotectin played a crucial role in renal repair after ischaemia/reperfusion-induced kidney
injury: S100A8/S100A9 inhibited M2-polarization of macrophages, thereby preventing the
induction of renal fibrosis and damage after AKI [5].
The prognosis of AKI crucially depends on the early and correct identification of the under-
lying condition. The earlier the treatment, the better the chance of ameliorating the renal func-
tion impairment [6]. Whereas post-renal AKI is easily detectable by ultrasound, the
differentiation between prerenal and intrinsic disease can be challenging. So far, there has been
no reliable biomarker capable of differentiating between these 2 conditions. Therefore, the
identification of calprotectin as a diagnostic marker may be of practical clinical interest. Ade-
quate clinical use of a diagnostic parameter, however, necessitates detailed knowledge on the
time-dependent changes of this parameter after renal injury. For example, it takes up to 2 days
for the levels of the most frequently used AKI biomarker, creatinine, to begin to rise. Therefore,
the identification of NGAL as an early marker of AKI evoked considerable interest. Elevated
urinary NGAL concentrations were reached within hours following ischaemic renal injury [7–
9]. Hence, NGAL is regarded as a kind of “troponin of the kidney” [10]. However, the time-
course of calprotectin secretion in the urine after renal injury remains elusive.
The present study makes use of nephron sparing surgery (NSS) for kidney tumours as a model
for ischaemia/reperfusion-induced tubular damage. In the majority of cases, NSS requires clamp-
ing of the renal artery for several minutes, thereby providing the opportunity to examine the
effects of ischaemia and reperfusion in an in vivo setting. Subjects undergoing NSS without clamp-
ing of the renal artery served as controls. Thus, this approach allowed the first characterisation of
the time-course of urinary calprotectin secretion in tubular injury in comparison to NGAL.
Methods
Study population
This study was approved by the local ethics committee of the Charité –University Hospital Ber-
lin and by the ethics committee of Northwest und Central Switzerland. All patients provided
written informed consent. Patients were referred to the Department of Urology at the Charité
–University Hospital Berlin or to the Department of Urology at the University Hospital Basel
for surgical treatment of renal tumours by NSS or living donor nephrectomy. The study popu-
lation included 42 patients, divided into 3 groups: 1 group of patients with renal ischaemia/
reperfusion injury and 2 control groups.
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Group 1 (iatrogenic renal ischaemia/reperfusion injury, n = 26): patients undergoing NSS
for renal tumours. The inclusion criterion was a resection of a solid renal mass necessitating a
temporary interruption of the renal arterial blood flow to control bleeding.
Group 2 (control group, no renal ischaemia, n = 6): patients undergoing NSS for renal
tumours without the need for renal artery clamping.
Group 3 (control group, no renal ischaemia, no surgery-related mechanical damage to the
remaining kidney, n = 10): patients undergoing nephrectomy as a living kidney donor.
For all 3 groups, exclusion criteria comprised pre-existing impairments of renal function
with an estimated glomerular filtration rate (eGFR)< 50 ml/min according to the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [11], urinary tract infections,
and bladder cancers. AKI was defined according to the Acute Kidney Injury Network (AKIN)
criteria as an increase in plasma creatinine levels 50% or 0.3 mg/dl [12].
Surgical technique
NSS (Groups 1 and 2) was performed by open surgery, laparoscopy, retro-peritoneoscopy, or
robot-assisted laparoscopic surgery. Living donor nephrectomy (Group 3) was conducted
retro-peritoneoscopically. In Group 1, surgery-related renal ischaemia was performed by
clamping the arterial renal pedicle with Satinsky vascular clamps in open surgery, or with Bull-
dog vascular clamps in endoscopic surgery. Indications for arterial renal pedicle clamping were
determined by the surgeon. The length of time of the blood flow interruption was documented
(clamp time). Nephro-protective methods, such as induction of surface hypothermia of the
kidney with ice slush or intravenous mannitol injections, were not applied.
Sample collection
At the beginning of the surgical procedure, a urinary indwelling catheter was placed and a pri-
mary urine sample was obtained for the assessment of baseline urinary calprotectin and NGAL
concentrations. During the intra- and post-operative courses, urine samples for the sequential
assessment of urinary calprotectin and NGAL were obtained after surgical kidney exposure
directly before clamping of the renal artery (Group 1), directly before tumour resection (Group
2), or directly before vessel and ureter ligation (Group 3). Urine samples were also collected in
all 3 groups at the end of the operation (approximately 2 h post-ischaemia). Thereafter, sam-
ples were obtained 6 h post-operatively (approximately 8 h post-ischaemia) and once daily for
the first 5 post-operative days. Plasma creatinine levels were measured prior to the procedure,
6 h post-operatively (approximately 8 h post-ischaemia) and once daily for the first 5 postoper-
ative days in all groups. In a small number of patients, we could not analyse samples at every
time point. In the overall study population, 13.5% (interquartile range, 5.3–18.5%) of urinary
calprotectin/NGAL samples are missing for each measurement point.
Measurement of urinary calprotectin and NGAL concentrations
Collected samples were stored at -20°C, without centrifugation, until calprotectin and NGAL
concentrations were assessed. Urine concentrations of calprotectin were quantified using the
PhiCal1 Calprotectin enzyme-linked immunosorbent assay (ELISA) kit (Immundiagnostik
AG, Bensheim, Germany) according to the manufacturer’s protocol, as previously published
[1]. Concentrations of NGAL were assessed using the NGAL Rapid ELISA Kit (Bioporto, Gen-
tofte, Denmark), as previously described [1]. This assay has been clinically validated [13]. We
did not assess urinary creatinine levels, as we have previously shown that the diagnostic perfor-
mance of urinary calprotectin concentrations was not improved when adjusted for urinary cre-
atinine [1,2].
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Statistical analysis
Continuous data were presented as the median and interquartile range (IQR). Data on an ordi-
nal or continuous level were analysed with the non-parametric Mann-Whitney-U test when
there was a comparison between 2 groups (e.g. Group 1 versus Group 2), and with the Kruskal-
Wallis test when there were> 2 groups (e.g. Group 1 versus Group 2 versus Group 3). A com-
parison of categorical parameters was performed using Fisher´s exact test. A non-parametric
analysis of variance (Kruskal-Wallis test, corrected for multiple comparisons with Dunn´s test
as a post hoc pairwise multiple comparison test) was used to test for significant changes from
baseline in the levels of calprotectin, NGAL, and plasma creatinine, and eGFR over the course
of the observation period. In accordance with the results of a preceding Shapiro-Wilk normal-
ity test and Q-Q plot, a non-normality Spearman’s correlation test was applied to determine
the association between urinary calprotectin or NGAL and ischaemic time or eGFR in Group
1. A linear regression test was performed to define independent prognostic factors for the max-
imum increase of urinary calprotectin and NGAL in Group 1. A p-value< 0.05 was regarded
as statistically significant. All statistical analyses were performed using SPSS Statistics 19 (SPSS
Inc., Chicago, Illinois, USA) or Graphpad Prism 6 (GraphPad Software, Inc., La Jolla, Califor-
nia, USA).
Results
Thirty-two patients who underwent NSS (Groups 1 and 2) and 10 patients who underwent a
living donor nephrectomy (Group 3) were included in this study. Epidemiological data, con-
comitant diseases, tumour characteristics, surgical data, renal parameters, and baseline urinary
calprotectin and NGAL concentrations for these patients are presented in Table 1. Clamping of
the renal artery during the surgical procedure was necessary in 26 patients (Group 1). The
median renal pedicle clamp time (ischaemic time) was 13.0 min (IQR, 4.5–20.3 min).
As presented in Fig 1/D1, the post-operative eGFR in Group 1 was slightly, but significantly,
decreased from 83.6 ml/min (IQR, 66.1–91.4 ml/min) to 67.2 ml/min (IQR, 48.7–81.4 ml/min,
Δ 16.4 ml/min, p = 0.049) after 24 h (post-operative day 1). Although eGFR was also decreased
6 h post-operatively, this was not significant (Δ 7.0 ml/min, p = 0.98, data not shown). Renal
function was recovered within 48 h (postoperative day 2) with eGFR of 75.4 ml/min (IQR,
48.8–83.8 ml/min). At discharge from the hospital, eGFR was 9.4 ml/min lower than the base-
line rate (p = 0.29). According to the AKIN criteria, 9/26 Group 1 patients, 1/6 Group 2
patients, and 9/10 Group 3 patients developed AKI.
There was a significant increase in both urinary calprotectin (p< 0.001) and NGAL
(p< 0.001) levels in response to renal ischaemia (Fig 1/A1 and 1/B1). Calprotectin was the
first to show a significant increase: approximately 2 h post-ischaemia, at the end of the opera-
tion (Δ 263.1 ng/ml, p = 0.009). NGAL levels were significantly increased 6 h post-operation
(approximately 8 h post-ischaemia, Δ 20.3 ng/ml, p = 0.01). Maximal NGAL and calprotectin
concentrations were reached at 48 h (post-operative day 2). NGAL increased from 7.0 ng/ml
(IQR, 2.9–13.8 ng/ml) to 64.0 ng/ml (IQR, 14.9–131.7 ng/ml). Urinary calprotectin levels
increased from 41.7 ng/ml (IQR, 11.1–148.8 ng/ml) to 2894.0 ng/ml (IQR, 558.7–6436.0 ng/
ml) within 48 h, after which the levels began to decrease. The maximal NGAL and calprotectin
concentrations were 9-fold and 69-fold higher than baseline values. At discharge, NGAL con-
centrations were still significantly higher than baseline levels (7.0 ng/ml [IQR, 2.9–13.9 ng/ml]
vs. 16.4 ng/ml [IQR, 10.9–76.7 ng/ml], p = 0.01). Urinary calprotectin concentrations returned
to 345.0 ng/ml (IQR, 96.82–1096.0 ng/ml) by post-operative day 5 (120 h). Calprotectin levels
at discharge were still significantly different from the pre-ischaemia levels (Δ 303.3 ng/ml,
p = 0.02).
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Table 1. Epidemiological data, concomitant diseases, tumour characteristics, surgical data, renal parameters, and baseline urinary calprotectin/
NGAL concentrations in the study population.
Group 1 Group 2 Group 3 p-value
NSS with ischaemia NSS without ischaemia Living donor nephrectomy
(n = 26) (n = 6) (n = 10)
Epidemiology
Male/Female 21 (80.8%)/5 (19.2%) 2 (33.3%)/4 (66.7%) 4 (40%)/6 (60%) 0.02
Age (years) 64 (54–75.25) 63 (43.25–69) 53 (46.25–61) 0.08
Body mass index (kg/m2) 26.6 (24.5–31.5) 24.6 (21.75–25.83) 24 (20–28) 0.07
Concomitant diseases
Diabetes mellitus 5 (19.2%) 0 (0%) 0 (0%) 0.24
Hypertension 16 (61.5%) 3 (50%) 2 (20%) 0.08
Pre-existing CKD 4 (15.4%) 1 (16.7%) 0 (0%) 0.40
Coronary heart disease 3 (11.5%) 2 (33.3%) 0 (0%) 0.16
Status after nephrectomy 2 (7.7%) 1 (16.7%) 0 (0%) 0.58
Status after NSS 2 (7.7%) 1 (16.7%) 0 (0%) 0.58
Medication on admission
ACE-I/ARB 13 (50%) 4 (66.7%) 1 (10%) 0.04
Diuretics 6 (23.1%) 1 (16.7%) 0 (0%) 0.22
Side
Right/Left kidney 10 (38.5%)/16 (61.5%) 3 (50%)/3 (50%) 1 (10%)/9 (90%) 0.24
Tumour characteristics
Type of tumour 0.19
RCC 23 (88.5%) 4 (66.7%) -
Oncocytoma 2 (7.7%) 1 (16.7%) -
Angiomyolipoma 0 (0%) 1 (16.7%) -
Other 1 (3.8%) 0 (0%) -
RCC histology 0.11
clear cell 17 (65.4%) 1 (16.7%) -
papillary 2 (7.7%) 2 (33.3%) -
chromophobic 4 (15.4%) 1 (16.7%) -
Staging of RCC 0.89
pT1a 17 (65.4%) 3 (50%) -
pT1b 5 (19.2%) 0 (0%) -
pT2a 0 (0%) 1 (16.7%) -
pT2b 1 (3.8%) 0 (0%) -
Tumour diameter (mm) 35 (22.7–41.25) 24.5 (12–79.25) - 0.54
Surgical data
Operation time (min) 212.5 (177.25–260) 154 (96.25–180.75) 183 (163.75–207.5) 0.003
Renal artery clamping (ischaemia) 26 (100%) 0 (0%) -
Ischaemic time (min) 13 (4.5–20.25) - -
Surgical approach 0.75 a
Open surgery 15 (57.7%) 3 (50%) 0 (0%)
Endoscopic surgery 11 (42.3%) 3 (50%) 10 (100%)
Laparoscopy (lap.) 6 (23.1%) 1 (16.7%) 0 (0%)
Robot-assisted lap. 4 (15.4%) 2 (33.3%) 0 (0%)
Retro-peritoneoscopy 1 (3.8%) 0 (0%) 10 (100%)
Renal data
eGFR on admission b (ml/min/1.73 m2) 84.6 (66.3–97.8) 71.4 (52.6–91.6) 96.4 (89.25–109.5) 0.37
Plasma creatinine on admission (mg/dl) 0.91 (0.83–1.01) 0.85 (0.77–1.49) 0.76 (0.65–0.84) 0.73
(Continued)
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In Groups 2 and 3, there were no significant changes in urinary calprotectin and NGAL
concentrations. In Group 2, renal function remained stable post-operatively with no significant
changes in plasma creatinine levels or eGFR (Fig 1/C2 and 1/D2). In Group 3, eGFR were sig-
nificantly decreased from 96.4 ml/min (IQR, 88.5–109.5 ml/min) at baseline to 53.0 ml/min
(IQR, 49.0–61.5 ml/min) at post-operative day 1, and remained low until post-operative day 5
(Fig 1/D3); this decrease was a result of the kidney donation.
Fig 2 presents the maximal changes in calprotectin, NGAL, and plasma creatinine concen-
trations, and eGFR within the 3 groups. Maximal concentrations of calprotectin and NGAL
were significantly higher in Group 1 than in Groups 2 and 3 (calprotectin 3665.0 ng/ml [IQR,
1671.0–5698.0 ng/ml] versus 0.0 ng/ml [IQR, 0.0–273.0 ng/ml] versus 433.5 ng/ml [IQR,
239.4–950.6 ng/ml], p< 0.001, Fig 2A; NGAL 75.1 ng/ml [IQR, 43.1–157.2 ng/ml] versus 11.1
ng/ml [IQR, 3.1–50.2 ng/ml] versus 22.3 ng/ml [IQR, 6.0–45.5 ng/ml], p = 0.0013, Fig 2B).
Changes in kidney function, as assessed by the maximum increase in plasma creatinine levels
and the maximum decrease in eGFR, were not significantly different in Groups 1 and 2
(p = 0.16 and p = 0.23, respectively). There was, however, a significant difference between
Groups 1 and 3 (p = 0.01 and p< 0.001, respectively) (Fig 2C and 2D).
Table 2 presents the univariate linear regression analysis for prognostic factors of the maxi-
mum calprotectin and NGAL increases in Group 1.
The linear regression model did not reveal any other significant prognostic factors for maxi-
mal calprotectin or NGAL elevation.
Correspondingly, the extent of the maximum calprotectin and NGAL increases in Group 1
were not associated with ischaemic time, according to Spearman’s correlation (Fig 3).
Discussion
Calprotectin is a biomarker that differentiates intrinsic from prerenal AKI. To date, however,
the time-dependent changes of calprotectin concentrations after intrinsic AKI have remained
elusive. A surgical procedure with clamping of the renal artery provides the opportunity to
examine the dynamics of renal biomarkers in an in vivo ischaemia/reperfusion injury model.
The first finding of the present study is that urinary calprotectin concentrations indeed reflect
tubular injury. Secondly, urinary calprotectin is more sensitive than plasma creatinine as it
detects tubular injury much earlier and with a higher dynamic range than plasma creatinine.
Previous studies of calprotectin in AKI comprised heterogeneous patient populations, includ-
ing those with glomerulonephritis, acute tubular necrosis, pyelonephritis, vasculitis, contrast-
induced nephropathy, and interstitial nephritis [1,2]. To the best of our knowledge, our study
Table 1. (Continued)
Group 1 Group 2 Group 3 p-value
NSS with ischaemia NSS without ischaemia Living donor nephrectomy
(n = 26) (n = 6) (n = 10)
Urinary biomarkers
Urinary calprotectin on admission (ng/ml) 41.72 (11.07–148.82) 78.91 (54.65–268.79) 36.35 (3.83–306.55) 0.17
Urinary NGAL on admission (ng/ml) 7.04 (2.85–13.84) 12.10 (4.84–18.65) 5.38 (3.20–9.3) 0.56
NSS, nephron sparing surgery of kidney tumours; CKD, chronic kidney disease; ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker; RCC, renal cell cancer; eGFR, estimated glomerular ﬁltration rate; NGAL, neutrophil gelatinase-associated lipocalin.
Continuous data are presented as median and interquartile range.
a applies only to NSS groups.
b calculated according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula.
doi:10.1371/journal.pone.0146395.t001
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Fig 1. Concentrations of (A) urinary calprotectin, (B) urinary neutrophil gelatinase—associated lipocalin (NGAL), (C) plasma creatinine, and (D) the
estimated glomerular filtration rate (eGFR) in patients undergoing nephron sparing surgery (NSS) for kidney tumours with renal pedicle clamping
(renal ischaemia, Group 1) or without renal ischaemia (Group 2), and in patients undergoing radical nephrectomy for living kidney donation
(Group 3). Data are presented as median and interquartile range. Asterisks indicate significant changes from baseline in a non-parametric analysis of
variance (Kruskal-Wallis test, corrected for multiple comparisons by Dunn’s test as a post hoc pairwise multiple comparison). p.o., post-operative. * p < 0.05,
** p < 0.01, *** p < 0.001.
doi:10.1371/journal.pone.0146395.g001
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is the first characterisation of the dynamics of calprotectin secretion in the urine over a defined
timeline in a homogeneous population of patients with only ischaemic tubular injury.
Ten years ago, the identification of NGAL initiated the current era of renal biomarker
research. In a population of 71 children undergoing a cardio-surgical procedure, it was shown
that NGAL could be used to monitor tubular injury. NGAL increased long before tubular
injury manifested as a rise in plasma creatinine levels [9]. Hence, NGAL was regarded as a kind
of “troponin of the kidney”. It predominantly reflects injury to the distal tubulus and consti-
tutes the best characterised urinary marker of tubular injury so far [10,14]. Therefore, in our
current study, we measured NGAL as the “gold standard biomarker” for tubular injury. So far,
4 different study groups have investigated the time-course of changes in urinary NGAL excre-
tion and plasma creatinine levels after renal ischaemia in NSS in humans [7,8,15,16]. In
Fig 2. Maximal change from baseline of (A) urinary calprotectin, (B) urinary NGAL, (C) plasma creatinine, and (D) eGFR in patients undergoing
NSS with renal renal ischaemia (Group 1) and NSS without renal ischaemia (Group 2), and in patients undergoing nephrectomy for living kidney
donation (Group 3). Data are presented as median and interquartile range. Asterisks indicate significant differences in a non-parametric analysis of variance
(Kruskal-Wallis test, corrected for multiple comparisons by Dunn’s test as a post hoc pairwise multiple comparison test). NSS, nephron sparing surgery for
kidney tumours; eGFR, estimated glomerular filtration rate. ns not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
doi:10.1371/journal.pone.0146395.g002
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Table 2. Univariate linear regression analysis for prognostic factors of themaximumurinary calprotectin increase (x—italics top line) and the max-







95% CI of B p-
value
Ischaemia time (min) a x 103.61 0.16 0.03 - 219.96–427.19 0.51
y 1.71 0.09 0.01 - 7.88–11.31 0.71
Ischaemia duration < or > 13 min x 2026.62 0.22 0.05 - 2471.17–
6524.40
0.36
y 84.45 0.31 0.10 - 44.43–213.34 0.19
Ischaemia duration < or >20 min x - 1224.16 0.12 0.02 - 6113.30–
3664.98
0.61
y - 38.53 0.13 0.02 - 182.13–105.07 0.58
Operation time (min) a x 13.01 0.18 0.03 - 18.05–44.07 0.40
y - 0.68 0.19 0.04 - 2.20–0.83 0.40
Renal artery clamping lap./open x - 218.46 0.03 0.001 - 3724.21–
3287.29
0.90
y - 143.64 0.35 0.13 - 303.79–16.51 0.08
Sex m/f x - 2696.36 0.18 0.03 - 6184.89–
2466.86
0.38
y - 91.62 0.14 0.02 - 284.6–140.29 0.49
Age x - 6.72 0.02 < 0.001 - 145.44–131.99 0.92
y - 2.23 0.14 0.02 - 9.94–4.46 0.50
BMI x 147.46 0.16 0.03 - 247.13–542.05 0.45
y 6.06 0.13 0.02 - 13.38–25.49 0.53
Diabetes mellitus x 1299.21 0.13 0.16 - 3062.78–
5661.21
0.55
y - 0.46 0.001 < 0.001 - 215.07–214.15 1.00
Hypertension x 2855.03 0.34 0.11 -497.03–6207.10 0.09
y - 8.66 0.02 < 0.001 - 182.48–165.15 0.92
Coronary heart disease x - 940.88 0.10 0.01 - 4737.23–
2855.47
0.62
y - 114.59 0.18 0.03 - 374.89–145.72 0.37
Chronic kidney disease x - 1725.45 0.15 0.02 - 6472.21–
3021.31
0.46
y - 91.69 0.17 0.03 - 322.91–139.53 0.42
Status after nephrectomy x - 1037.73 0.07 0.005 - 7525.09–
5449.62
0.74
y - 50.61 0.07 0.005 - 367.31–266.08 0.74
Status after NSS x - 642.54 0.04 0.002 - 7138.97–
5853.89
0.84
y - 78.49 0.10 0.01 - 394.18–237.20 0.61
ACE-I and/or ARB x 131.09 0.16 < 0.001 - 3333.67–
3595.86
0.94
y - 70.38 0.18 0.03 - 236.93–96.16 0.39
Diuretics x 10.36 0.001 < 0.001 - 4101.90–
4122.63
1.00
y - 77.41 0.16 0.03 - 275.49–120.67 0.43
Baseline plasma creatinine (mg/dl) x 57.94 0.002 < 0.001 - 10215.50–
10331.39
0.99
y 45.82 0.04 0.001 - 455.33–546.97 0.85
Baseline eGFR (CKD-EPI) (ml/min per
1.73 m2)
x 11.70 0.05 0.003 - 86.30–109.69 0.81
(Continued)
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accordance with previous studies [7–9,15,17,18], urinary NGAL significantly increased after
renal ischaemia in our population. Hence, the average ischaemic time of 13 min with subse-
quent reperfusion indeed led to tubular injury in the remaining renal parenchyma. Urinary cal-








95% CI of B p-
value
y 0.47 0.04 0.002 - 4.32–5.25 0.84
Post-operative AKI b x 1452.79 0.17 0.03 -2137.30–
5042.88
0.41
y 2.28 0.005 < 0.001 - 175.51–180.06 0.98
Calprotectin at baseline (ng/ml) x - 2.48 0.09 0.01 15.27–10.32 0.69
y 0.24 0.17 0.03 - 0.37–0.86 0.42
Calprotectin at end of operation (ng/ml) x 0.07 0.02 < 0.001 - 1.55–1.70 0.93
y - 0.02 0.11 0.01 - 0.10–0.06 0.60
Calprotectin at p.o. day 1 (ng/ml) x - 0.15 0.07 0.01 - 1.15–0.85 0.75
y - 0.03 0.29 0.08 - 0.09–0.02 0.21
NGAL at baseline (ng/ml) x - 29.50 0.10 0.01 - 159.96–100.98 0.64
y - 1.04 0.10 0.009 - 7.78–4.96 0.65
NGAL at end of operation (ng/ml) x - 22.53 0.12 0.02 - 104.61–59.54 0.58
y - 1.65 0.18 0.03 - 5.63–2.34 0.40
NGAL at p.o. day 1 (ng/ml) x - 45.81 0.25 0.06 - 130.26–38.64 0.27
Y - 3.50 0.34 0.12 - 8.10–1.11 0.13
m, male; f, female; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; lap, laparoscopic; NSS, nephron sparing surgery for kidney tumours; AKI, acute kidney injury; i.o., intra-operative; p.o., post-operative; B,
regression co-efﬁcient; R, correlation co-efﬁcient; CI, conﬁdence interval.
a Pearson correlation shows a signiﬁcant association between ischaemic time and operation time (R = 0.67, p = 0.001).
b AKI was deﬁned as a plasma creatinine increase of > 50% or > 0.3 mg/dl from baseline [12].
doi:10.1371/journal.pone.0146395.t002
Fig 3. Association between (A) the maximum urinary calprotectin increase and ischaemic time and (B) the maximum urinary NGAL increase and
ischaemic time in Group 1 (NSS with renal ischaemia) in a linear regression model, as assessed by Spearman’s correlation test.Regression lines
are plotted. Linear regression model: A: R = 0.16, B = 103.61 (95% CI -219.96–427.19), p = 0.51; B: R = 0.09, B = 1.71 (95%CI -7.88–11.31), p = 0.71.
Spearman’s correlation: A: R = 0.29 (95%CI -0.19–0.66), p = 0.21; B: R = 0.26 (95%CI -0.22–0.64), p = 0.26. NSS, nephron sparing surgery for kidney
tumours; B, regression co-efficient, slope of the regression line; R, correlation co-efficient; CI, confidence interval.
doi:10.1371/journal.pone.0146395.g003
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secretion of calprotectin in the urine after ischaemic renal injury are not available. Calprotectin
concentrations showed a 69-fold increase after the surgical procedure. Interestingly, both cal-
protectin and NGAL concentrations increased in every single patient in Group 1, thus yielding
a sensitivity of 100% for the detection of ischaemia/reperfusion injury. The 2 control groups,
who underwent NSS without clamping of the renal artery or with a complete nephrectomy (liv-
ing donor nephrectomy), revealed that the increase in urinary biomarker concentrations can-
not be explained by other peri-procedural factors. Such factors include non-ischaemic surgical
kidney trauma, haematuria, leukocyturia, an indwelling catheter, or anaesthesia. Neither cal-
protectin nor NGAL concentrations changed after the procedure in these control groups.
These findings are important since both NGAL and calprotectin concentrations increase in the
setting of leukocyturia [1].
Knowledge of the time-dependent dynamics of calprotectin in AKI is essential before it can
be potentially implemented in daily clinical practice. The present findings show that concentra-
tions begin to rise shortly after ischaemia. Increases in urinary calprotectin and NGAL concen-
trations were evident approximately 2 h (end of operation) and 8 h (6 h post-operation),
respectively, after ischaemia. The maximum increase in the levels of both proteins was seen
after 48 h, with a 69-fold increase over baseline in calprotectin levels and a 9-fold increase over
baseline in NGAL levels. One-hundred-and-twenty hours after renal pedicle clamping, both
urinary calprotectin and NGAL concentrations were still elevated by 8-fold and 2-fold, respec-
tively. The onset of this increase, thereby, largely precedes any possible changes in plasma cre-
atinine levels, which usually occur> 24 h after kidney injury [9]. The rapid onset of the
increase in calprotectin levels is comparable to NGAL. NGAL levels also reached a maximum
at day 2 after ischaemia/reperfusion injury. Although the curves seem rather similar, the
NGAL increase becomes statistically significant later than the calprotectin increase. With
regard to the findings of previous studies, like those of Mishra et al. [9], we must consider the
reasons why NGAL levels do not start rising earlier. The average ischaemic time in our study
was much shorter (13 min) than the time noted in the analogue studies of Abassi et al. (32
min) [7] and Parekh et al. (23 min) [8]. Consequently, the maximum urinary NGAL concen-
tration 48 h after ischaemia-induced injury in the study from Abassi et al. was approximately
twice as high as that in our study. This is a potential explanation for the fact that the increases
in NGAL levels became significant earlier in these studies (2–3 h post-ischaemia) than they did
in our study. One-hundred-and-twenty hours after renal pedicle clamping, the urinary calpro-
tectin level was still 8-fold higher than the baseline level. Therefore, a “false-negative” calpro-
tectin test result is improbable within 5 days after the onset of intrinsic AKI. In summary, the
increase in calprotectin levels in response to ischaemia is rapid, strong, and perpetuates for sev-
eral days.
In the current study, eGFR is slightly, but significantly, reduced in Group 1 patients at day 1
and resembles baseline values thereafter. This indicates that the ischaemia-induced tubular
injury, and perhaps also the resection of the tumour and surrounding functional parenchyma,
induced only a slight impairment in renal function. Hence, both NGAL and calprotectin con-
stitute very sensitive markers of tubular injury. Accordingly, calprotectin has been recently
shown to sensitively detect ischaemic tubular injury in renal allografts at the time of transplan-
tation [19]. Higher urinary calprotectin concentrations predicted impaired kidney function 4
weeks, 6 months, and 12 months post-transplantation.
With regard to the findings in renal transplant recipients, it appears possible that calprotec-
tin does not only reflect tubular injury in a “black or white”manner, but it may also be able to
provide information on the extent of the injury. Due to the minor effects of ischaemia on eGFR
in the present study, we could not adequately address this hypothesis in our patient population.
Alternatively, we analysed the association between biomarker concentrations and ischaemic
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time. However, neither maximum calprotectin nor NGAL concentrations were significantly
associated with ischaemic time. In the literature, there are inconsistent reports regarding the
association between ischaemic time and tubular injury with subsequent loss of renal function
[7,8,15,16,18]. The longer the ischaemic time, the more probable it is that an association
between this parameter and an NGAL increase could exist. Among all cited studies on urinary
NGAL in NSS, only Abassi et al. found a significant association [7,8,16,18].
Are the findings of this study indeed of practical clinical interest? After a decade of research,
what is the future perspective for renal biomarkers? In the past 10 years, much effort has been
invested in the identification and characterisation of AKI biomarkers. The overwhelming
majority of the resulting publications focused on the time-point of the AKI diagnosis in order
to improve early diagnosis rates and, hopefully, outcome. To date, several biomarkers, includ-
ing NGAL and kidney injury molecule, have been identified [10,14,18,20–23]. Indeed, these
biomarkers are more sensitive and detect renal damage earlier than conventional markers like
plasma creatinine. However, given that we are able to diagnose AKI earlier, what are the clinical
benefits of this information? In the setting of surgery or an Intensive Care Unit (ICU), the ben-
efit is “best medical care” with regard to, for example, fluid substitution and blood pressure
control. “Best medical care”, however, should be provided independent of any biomarkers.
Therefore, the utility of reliable renal biomarkers may be applicable somewhere else. We
believe that biomarkers may be of practical clinical help in the differential diagnosis of different
forms of AKI. In contrast to the setting of an ICU where the majority of patients have shock-
or drug-associated acute tubulus necrosis (ATN), the identification of the cause of AKI in most
other clinical situations is difficult. Whereas the diagnosis of post-renal AKI is easily made by
ultrasound, the differentiation between prerenal and intrinsic AKI may be difficult. In the
absence of a reliable laboratory marker, response to fluid repletion is still regarded as the gold
standard for differentiation between these entities. Return of renal function to baseline within
24 to 72 h is considered an indication of prerenal AKI, whereas persistent renal failure indicates
intrinsic disease. However, several intrinsic causes, such as crescentic glomerulonephritis,
require an immediate biopsy in order to avoid a delay in the initiation of immunosuppressive
therapy. In these patients, the 3-day watchful waiting approach before a biopsy procedure is
unacceptable. Calprotectin has been proven to be a helpful tool in this context [1,2]. It is largely
increased in intrinsic AKI, whereas it is comparable to healthy controls in prerenal disease.
Pyuria and urothelial carcinoma can increase calprotectin concentrations independent of AKI
and must be taken into account as potential confounders [1,24]. The findings of the present
study render further support to the role of calprotectin as a biomarker in AKI, since ATN is a
classic example of intrinsic AKI. Calprotectin could be used, for example, as a lateral flow test.
A test like this already exists for stool samples. Coming back to the question of whether the
present findings can indeed be of clinical significance: yes, they can. Knowledge of the time-
dependent dynamics of a biomarker is a crucial pre-requisite for its use in clinical practice. The
fact that concentrations are significantly elevated within 2–3 h and remain increased for at
least 5 days after the onset of renal injury meets clinical needs.
This study is limited by the duration of the observation period. Since calprotectin concen-
trations are still increased at day 5 (end of follow-up), it was not possible to determine the
length of time it takes for its return to baseline levels. It was not possible to motivate the whole
study population to provide further urine samples after discharge from hospital.
The present study shows that ischaemia/reperfusion-induced AKI leads to significantly
increased urinary calprotectin concentrations within 2–3 h, reaching a maximum at 48 h with
a subsequent decrease thereafter. Levels remain increased for at least 5 days. The detection sen-
sitivity for ischaemia/reperfusion-induced tubular injury was 100% in the present study popu-
lation. This characterisation of the time-dependent dynamics of this new urinary biomarker is
Dynamics of Urinary Calprotectin after Renal Ischaemia
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a pre-requisite feature for its potential clinical implementation in the differentiation of prerenal
and intrinsic AKI.
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